Drug Transporter (DT) Information

General Information of DT
DT ID DTD0249
Gene Name SLC29A3
Protein Name Equilibrative nucleoside transporter 3
Gene ID
55315
UniProt ID
Q9BZD2
TCDB ID
2.A.57.1.6
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6OB6_A

Identity: 34.537%

Minimized Score: -1052.763 kcal/mol

Detail: Structure Info

Synonyms Solute carrier family 29 member 3; hENT3; SLC29A3; ENT3; HJCD; PHID; HCLAP
DT Family Equilibrative Nucleoside Transporter (ENT) Family ;
Tissue Specificity Widely expressed in both adult and fetal tissues. Highest levels in placenta, uterus, ovary, spleen, lymph node and bone marrow. Lowest levels in brain and heart.
Function This transporter mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). Mediates transport of adenine, adenosine and uridine, as well as several nucleoside analog drugs, such as anticancer and antiviral agents, including cladribine, cordycepin, tubercidin and AZT and it does not transport hypoxanthine.
Endogenous Substrate(s) Adenine; Adenosine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Cladribine
 Approved Drug Info Hairy cell leukemia 2A82.2 [1]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Cordycepin
 Phase 1 Drug Info Leukemia 2A60-2B33 [1]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Adenosine
60961
EM Info Identified using ENT3 knockout mice [2]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Cladribine Approved Drug Info Xenopus Oocytes-ENT3 Km = 1860 microM [1]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Cordycepin Phase 1 Drug Info Xenopus Oocytes-ENT3 Km = 1860 microM [1]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Tubercidin Investigative Drug Info Xenopus Oocytes-ENT3 Km = 1860 microM [1]
References
1 Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
2 Adult stem cell deficits drive Slc29a3 disorders in mice. Nat Commun. 2019 Jul 3;10(1):2943.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.